WCLC 2020: Updates from the CHRYSALIS trial and what it means for patients with NSCLC

WCLC 2021 HighlightsПодробнее

Immunotherapy updates from WCLC 2021Подробнее

ASCO 2021 Lung Recap: Amivantamab and Mobocertinib for EGFR Exon 20Подробнее

Alex Spira, MD, PhD, FACP, shares thoughts on the Phase I CHRYSALIS study presented at ESMO 2020Подробнее

Latest in EGFR-positive NSCLC with exon 20 insertion mutationsПодробнее

WCLC 2023 highlights: FLAURA2 and EGFR exon20-targeting TKIsПодробнее

Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLCПодробнее

CHRYSALIS trial update in NSCLCПодробнее

CHRYSALIS: Amivantamab for EGFR exon 20 insertion mutant NSCLCПодробнее

2021 ASCO Direct Jacksonville | Local Lung Cancer Summary | Dr. John VuПодробнее

CHRYSALIS: amivantamab in wild-type, pre-treated NSCLCПодробнее

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLCПодробнее

Amivantamab and Mobocertinib for EGFR Exon-20 Disease - Lung Cancer Video LibraryПодробнее

Q&A: What is the Efficacy of Amivantamab and Lazertinib? - Targeted Therapies in Lung Cancer 2023Подробнее

Dr. West Discusses Upcoming Important Clinical Trials ResultsПодробнее

2021 West Oncology APP | Lung Cancer Treatments UpdateПодробнее

2021 ASCO Direct San Francisco | Metastatic Lung Cancer Summary | Dr. Ravi SalgiaПодробнее

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLCПодробнее

How clinical trials work: COVID-19 and beyondПодробнее